Index

25-hydroxy-vitamin D, 281

Absence from school, 74, 89, 191, 312 Abuse, 303 negative behaviors, 303 substance abuse, 296-297 Acetaminophen, 225 for back pain, 225 for low blood pressure, 225 ACL. See Anterior cruciate ligament ACR classification, 111 Activity clubs, 338

Acute apophyseal avulsion injuries, 253 Adaptability dimension, defined, 313 Adherence enhancing interventions, 96-100 behavioral interventions, 98-99 educational strategies, 97-98 organizational interventions, 99-100 to increase psychosocial support, 99 Adherence, 86-87, 331 adherence enhancing interventions, 96 assessment, 87 defined, 86 improvement, 86, 97 non-pharmacological therapies, 89-91 avoidance of specific risk factors, 90 clinic attendance, 90-91 occupational therapy, 89-90 physical therapy, 89 and parental supervision, 99 pharmacological therapies, 88 poor adherence, 92-96 to exercise, 89

Adolescence and back pain, 208-209 and chronic illness, 17-19 cognitive functioning, 15 defined, 2

developmental issues, 14-17 information processing, 14-15 internalizing symptoms, 22 key tasks, 4

medical disorders in, 297-301 and rheumatic diseases, 19-24 disease spectrum, 19-21 diversity, 19-21 self-management, 3 sexual behavior, 292-297 and social functioning, 157-158 transition to adulthood, 345-361 Adolescent health care, 4, 6, 71 educational interventions for, 371-373 environmental aspects, 317 key principle, 4-6 lack of training and, 370-371 multidisciplinary nature, 6-7 parental involvement, 316 Adolescent pathways, typology, 16 Adolescent rheumatology clinical microsystem, 390-393 Adolescent-friendly rheumatology services, 65-67, 72 developmental strategies, 73t-74t Adolescent-parent discrepancies, 76 Adolescent-parent dynamics, 315 assessment in context of chronic condition, 315-317

t = location of tables. f=location of figures.

[Adolescent-parent dynamics assessment in context of chronic condition] different perspectives, 315-316 parental advocacy, 316-317 parental needs, 316 psychosocial family history, 315 Adrenarche, 37, 52, 53t Adult arthritides, 149

relationship to JIA, 149-154 Adult inflammatory myopathies, 119t versus childhood, 119t-120t Adulthood, legalities, 351 Adult-oriented systems, 353 Alcohol abuse, 297 Allodynia, 186-187, 188, 219 Alopecia, 124-125 Ambulatory-care setting, 71 Amenorrhea postpubertal onset, 53t differential diagnosis of, 53t American adolescent, birth rates, 295t American College of Rheumatology, 111, 178, 188

American College of Rheumatology

Damage Index, 178 Aminosalicylates, 136

for bowel disease, 136 ANA. See Anti-nuclear antigen ANCA, 115, 117, 216 Anemia, 128 in JIA, 216

in systemic sclerosis, 128 Aneurysmal bone cysts, 219 Angiofollicular lymph node hyperplasia.

See Castleman's disease Anhydrosis, 124

in localized scleroderma, 124 Anorexia, 119t, 120 in juvenile dermatomyositis, 120 in malignant tumors, 218 Anterior cruciate ligament (ACL), 215, 242 case study, 242 Lachman test, 243f mechanism of system, 215t physical examination, 215t segond fracture of, 244f Anterior superior iliac spine, 253, 254t, 255f avulsion injury, 255f mechanism, 254t physical findings, 254t Anti-bullying policies, 339

Anti-centromere antibody, 127 in systemic sclerosis, 127-128 Anti-nuclear antigen, 126 in localized scleroderma, 126 in systemic sclerosis, 128 Anti-Saccharomyces cerevisiae antibody

(ASCA), 216 Anti-Scl 70 antibodies, 127, 128

in systemic sclerosis, 127 Antithymocyte globulin, 128 for Systemic sclerosis, 128 Anti-tumor necrosis factor, 88 Anxiety, 159-160, 187, 191-193, 402 causes, 159-160 in JIA, 159 Apophyseal ring injuries, 213, 222 Apprehension test, patellar instability, 238f Archives of Disease in Childhood, 374 Arthralgia, 115, 121, 124, 216 in polyarteritis nodosa, 115 in juvenile dermatomyositis, 121 in viral arthritis, 134 Arthritis, 93, 117, 121, 161 bacterial, 133t enthesitis-related arthritis, 152-153 gonococcal arthritis, 133t joint swelling in, 121 problems with sexual activity, 161 of spine, 215 viral arthritis, 134t ASCA. See Anti-Saccharomyces cerevisiae antibody Assessment, 192-197 adolescent-parent dynamics, 315-317 chronic pain, 192-197 parental needs, 316 of pubertal delay, 49-50 skills, 72-75 of strature, 46-47 Asthma, 297, 299 Atrophy, 125-126 in disc disease, 251 facial, 125f in juvenile disease, 119t tongue, 125 Autoimmune disease. See Systemic lupus erythematosus Autoimmune rheumatic disease, 114t causes, 114t Autonomic dysfunction, 187

Avascular necrosis, 173 Avulsion injury, 255f anterior superior iliac spine, 255f Azathioprine, 113, 117, 172, 173 for pulmonary disease, 130t for sarcoid, 117 for SLE, 172, 173

Back pain, 108, 187, 208-221 algorithmic approach to diagnosis of causes, 220f-221f associated factors, 209 in athletes, 211 causes of, 209-222

idiopathic pain, 220-222 infections, 217-218 mechanical, 209-215 psychogenic, 219 rheumatic, 215-216 tumors, 218-219 vascular, 217 diagnostic approach, 222-224 etiology, 207 management, 222-224 mechanical problems, 209-215 patterns of clinical presentation, 222-224 physical examination patterns, 224 symptom pattern, 222-224 prevalence, 209 prognosis, 225-226 web resources, 226 Bacterial arthritis, 133t causal agents, 133t clinical characteristics, 133t pattern of arthritis, 133t Bacterial pneumonia, 119t Bartonella henselae, 217

as cause of vertebral osteomyelitis, 217 Bath Adolescent Pain Questionnaire, 197 Behavioral interventions, 98-99

key issue, 98 Behcet's disease (BD), 117-118 Benign bone tumors, 219 aneurysmal bone cysts, 219 eosinophilic granulomas, 219 osteoblastoma, 213, 219 osteoclastomas, 219 osteoid osteoma, 137, 219, 222 Benign tumors, 137, 222

[Benign tumors]

musculoskeletal system, 137 Bidirectional interview strategy, 75 Birmingham Residential Program, 335 Birmingham U.K. Residential Summer Camp, 336t characteristics, 336t Bisphosphonates, 175, 281-282

adverse effects, 282 Blackouts, 187 in autonomic dysfunction, 187 in pain, 187 Bloody diarrhea, 136

in inflammatory bowel disease, 136 Blurred vision, 187 in autonomic dysfunction, 187 in pain, 187, 198 Body image, 157, 160-161

impaired, 20t Bone accretion, 39 Bone age, 50

assessment, 50 Bone biochemical markers, 278t formation, 278t resorption, 278t Bone density, 270 determinants, 270

effects of rheumatic diseases, 271-273 Bone derangements, 273 Bone growth, 268-269, 279

associated factors, 268-269 Bone health, 175 promotion, 279-281 in SLE, 175 Bone health promotion, 279-281 calcium, 279-280 physical activity, 281 protein intake, 280 vitamin D, 280 Bone mass accrual, 269-270 Bone mass acquisition, 269-270 effect of puberty on bone mass, 269-270 specific determinants of bone density, 270 heredity, 270 nutrition, 270 physical activity, 270 Bone mass measurement, 276

clinical problems in pediatrics, 276-278 Bone metabolism markers, 278-279

Bone mineral density (BMD). See Low bone mineral density Bone scintigraphy, 217, 219 Bone tumors, 137-138, 219 Bony fracture, 154 Bracing, 224

for Scheuermann's disease, 211 British Paediatric Surveillance Unit, 108 Broadband ultrasonic attenuation (BUA), 276 Brucella, 135t clinical characteristics, 135t pattern of arthritis, 135t Bulimia nervosa, 302 prevalence, 302

Calcaneal apophysitis, 260-261 Calcaneal squeeze test, 260, 261 Calcinosis, 119t, 121 elbow, 121f in juvenile disease, 119t Calcitonin, 283 Calcium, 279-280 Capillary dilatation, 121f Cardiovascular health, 176

in SLE, 176 Case study, 118, 242, 251, 255 ACL injury, 242

chronic Salter Harris I fracture of the distal radius in gymnasts, 262 disc disease, 251 juvenile dermatomyositis, 118 knee effusion, 242 knee injury, 237 MCL injury, 243 patellar dislocations, 246 patellar tendonitis, 245 shoulder pain, 257

slipped capital femoral epiphysis (SCFE), 253 stress fractures, 255 Casting, 89

Castleman's disease, 139 Catastrophizing, defined, 22 Catecholamine-O-methyltransferase (COMT)

activity, 186 Central nervous system (CNS), 176 events, 177

impact on functional ability, 177 involvement with SLE, 176-177 Changing schools, 75

Chapel Hill Consensus Conference (1994), 111 Chaperone, 70 Child, 25, 32 dispositional attributes, 25 and illness, 22-24 mi1d parental height range, 32 nonaccidental injury to, 214-215 Childhood chronic pain. See also Chronic pain Childhood Myositis Assessment Scale

(CMAS), 122 Childhood pain, 184 Childhood-onset scleroderma, 123 collagen synthesis, 124 T cell activation, 124 vascular activation, 123 CHIPS. See Chronic Illness Peer Support Chlorambucil, 152, 157 for amyloidosis, 152 for JIA, 157 Chronic illness, 329 adolescence and, 17-19 ChIPS program, 332-333 development issues and, 14-19 and friendship, 329-330 prevalence, 292t Chronic Illness Peer Support (ChIPS), 332-333 Chronic neurologic and cutaneous articular syndrome (CINCA), 138 Chronic pain, 183-201 assessment, 192-197 impact of pain, 196 important aspects of physical examination, 194-195 clinical presentation, 186 epidemiology, 183-184 etiology, 184-186 environmental, 185 genetics, 185 illness, 184-185 injury, 185

pathophysiological, 185-186 psychosocial factors, 185 general features, 186-189 impact on quality of life, 189-192 assessment, 192-197 key areas affected by pain, 190-192 medical therapies, 199 multidimensional pain measures, 197 outcome, 200-201 pain education, 197-199

[Chronic pain] pathogenesis, 184-186 physiological measurements, 197 prevalence, 184 rehabilitation, 199-200 Chronic pain syndromes, 188, 187 classification, 187-189

complex regional pain syndromes, 188 diffuse idiopathic pain (DIP)

syndromes, 188 localized idiopathic pain syndrome, 188 Chronic recurrent multifocal osteomyelitis

(CRMO), 132, 136 Chronic rheumatic condition, 401

living with, 401-409 Chronic Salter Harris I fractures, 263 case study, 263 treatment, 263 Churg-Strauss syndrome (CSS), 117 Ciclosporin A, 122

for juvenile dermatomyositis, 122 Cinncinati Children's Hospital Medical

Center, 388 Circular questioning, 76, 318 Classical vasculitis, 154 Clinic appointments, 90-91 Clinic attendance, 90-91 Clinic visits, 95, 319

preparation, 319 Clinical microsystems, 384, 390, 391 anatomy, 391, 392f defined, 390 patterns, 391 physiology, 391, 393f professionals, 391 purpose, 391 Clinical value compass, 388, 388, 393, 397 Cognitive development, 72, 74-75 areas influenced by, 74 assessment of, 72 effect of chronic illness, 74 Cognitive transformations, 14-15

Piaget's model, 14 Cohesion dimension, defined, 313 Common sports knee injuries, 235t-236t mechanism of injury, 235t-236t physical examination, 235t-236t Communication skills, 314, 374 negative, 314 positive, 314

Communication strategies, 76-79 circular questioning, 318 importance of respect, 77 importance of the first question, 76 importance of time and listening, 77 trigger questions, 77, 78t turn-taking, 317

verbal plan for the consultation, 76 Competence, 68, 370, 371 Complex regional pain syndrome (CRPS), 184, 188-189, 197 diagnostic criteria by ISAP, 189t Compliance, 86, 170 Concordance, 87 Concordant consultation, 87 Confidentiality, 67-70 in consultation, 68 practical aspect of, 68 Consent, 68

Consultation, 68, 76, 197

verbal plan for, 76 Contiguous osteomyelitis, 132 Contraception advice, 109t Contraceptive pills, 173 Coronary heart disease (CHD), 176 Corticosteroids, 113, 122, 157, 172, 174 for juvenile dermatomyositis, 122 for polyarteritis nodosa, 115 for pulmonary disease, 130t for SLE, 172 for systemic sclerosis, 128 side effects, 172 slowed growth, 174 vitamin D metabolism and, 280 Crisis, defined, 314

CRMO. See Chronic recurrent multifocal osteomyelitis CRPS. See Complex regional pain syndrome CSS. See Churg-Strauss syndrome Cutaneous leukocytoclastic vasculitis, 113t Cyclophosphamide, 109, 115, 123, 172, 173 for polyarteritis nodosa, 115 for premature ovarian failure, 173 side effects, 173 for SLE, 172, 173

Dactylitis, 153, 215 Daily hassles, 24

Dartmouth microsystem improvement ramp, 395f Death, 303-304 homicide, 304

motor vehicle accidents, 303 suicide, 303-304 violence, 303 Decision-making, 87 Deflazacort, 54

for short stature, 54 Delayed puberty, 48, 49-50, 56. See also Pubertal delay case study, 59-61 clinical examples, 59-61 differential diagnosis, 51t-52t management, 56 short courses for, 56-57 treatment, 56 Dental loosening, 129t Depo-provera injections, 173

for contraception, 173 Depression, 74, 302, 136, 158, 159-161, 302 causes of 159-160 incidence in adults with JIA, 159 sequelae of, 302 Dermal vessels, 117

IgA deposition, 117 Development, 22, 311. See also Normal growth family dynamics and, 311-315 impact of illness on, 22-24 normal growth and, 31-38 pubertal, average age, 40t skeletal growth and, 268-269 DHEA-sulphate, 52

Diabetes mellitus, 299. See also Medical disorders

Diet, 171 bone health promotion, 279 concerns in SLE adolescents, 171 Differential diagnosis, 51 amenorrhea postpubertal onset, 53t delayed puberty, 51t-52t short stature, 48t-49t Diffuse disease, 127 Diffuse idiopathic pain (DIP), 185, 188 DIPEx charity, 374, 374 Disability, 349-352 as an issue, 109t possible answers, 109t

[Disability] and employment, 162 in JIA, 158

pain-associated disability, 190f Disability support services (DSS), 349 Disc disease, 251-252 case study, 252 complications, 251 treatment, 252 Discitis, 217-218 Discrimination, 163 at workplace, 163 Disease-modifying anti-rheumatic drugs

(DMARDs), 88 Disease-related questions, 78t Disk degeneration, 210 Disk herniation, 207, 212, 222-223 Doctors. See Health professionals D-penicillamine, 127 for localized scleroderma, 127 for pulmonary disease, 130t Drop out, 121f

Dual-energy X-ray absorptiometry, 273, 275 DXA. See Dual-energy X-ray absorptiometry Dysplasia, 126 skin, 126

Education, 349 effect of pain on, 191 importance of, 97-98 in school, 174

school to post-secondary, 349-350 training needs for health professionals, 367-371

Educational interventions, 97, 371-372

evidence for health care, 371-372 Educational strategies, 97-98 Effective communication, 71

barriers to, 67t Egocentric, 14 defined, 14 Elbow, 261-262 injuries, 261

medial epicondyle apophysitis, 261-262, 262f showing calcinosis, 121f Embedded systems, 386f organizational layers, 386f

Empathy, 72, 314 Enthesitis, 152

Enthesitis-related arthritis (ERA), 59, 152-153, 215 ILAR criteria for, 153t versus related adult disorders, 153t Epidural abscess, 218 Epilepsy, 299-300 incidence of, 300 Erythema, 124, 115 palms, 115 skin, 124 Esophageal blood loss, 128 in systemic sclerosis, 128 Essential cryoglobulinemia vasculitis, 113t Estrogen, 37

role of, 37, 39 Etrinate, 127

for localized scleroderma, 127 European Training in Effective Adolescent Care and Health (EuTEACH), 371, 373

Evidence-based improvement equation, 390f Ewing's sarcoma, 138, 219 Exercise adherence, 89 Extended oligo-arthritis JIA, 150 Eyelid heliotrope discoloration, 121f

Facial atrophy, 125f Facial hair, 39 development, 39 growth, 173 Facial swelling, 120

Familial cold autoinflammatory syndrome

(FCAS), 138 Familial Mediterranean fever (FMF), 138-139 Family Adjustment and Adaptation Response Model, The, 314 Family, 99, 161-162, 191-192 adolescent development and, 311-315 dysfunction in, 99 functioning, 313-315 role in managing JIA, 161-162 Family communication, 314 Family dynamics, 311-315 and adolescent development patterns of family functioning, 313-315 role of parents, 312 Family functioning, patterns of, 313-315

Fat pad impingement, 235t, 245-246 mechanism of injury, 235t physical examination, 235t Fatigue, 74, 120, 190, 330 in JIA, 330

in juvenile dermatomyositis, 120 pain and, 187, 196t in tumors, 218 Female, 34 growth reference chart, 34f height velocity chart, 36f onset of puberty, 38

physiological changes during puberty, 38 pubertal development, 39f pubertal onset in, 37 Fever, 120 in epidural abscess, 218 in juvenile dermatomyositis, 120 in Kawasaki disease (KD), 115 in sarcoid, 117

in systemic onset juvenile idiopathic arthritis, 151 in vertebral osteomyelitis, 217 Fibromyalgia, 186, 220 First question, importance of, 76 Flaring, 172

prevention, 172 Follicle stimulating hormones (FSH), 36-37 high levels, 51t low levels, 51t Forgetfulness, 90, 93

Friendships, 329-342. See also Peer support and chronic illness, 329-330 disclosure in, 332 internet, 341 mobile phone, 340-341 role of health professionals, 340 role of parents, 340 role of teachers, 336-338 in schools, 335-340 Full height attainment, 37-38 Functional ability, 177

impact of CNS events, 177 Fundamental skill, 72

General health questions. See Well-being questions German cohort study, 189 GH-IGF-1 axis, 45, 45f

Giant cell arteritis, 112t incidence, 112t Glomerular mesangium, 117

IgA deposition, 117 Glomerulonephritis, 117 Glucocorticoids, 46 Gonadal hormones, 269 Gonadotrophin releasing hormone

(GnRH), 35 Gonococcal arthritis, 133t clinical characteristics, 133t pattern of arthritis, 133t Gottron's patches, 121

in hands, 121f Granulomatous vasculitides, 116-117 Churg-Strauss syndrome, 117 incidence, 112

Wegener's granulomatosis, 116-117 Groin, 252-253

case study, 252-253 Growing up, 345-361, 405-409 general principles, 346-347 and going out, 405 looking after yourself, 406-407 meeting someone special, 409 at school, 407-408 world of work, 408-409 Growth data, 32 Growth failure, 39-40, 44, 52-53 assessment, 59 contributing factors to, 44 hemoglobinopathies, 217 mechanisms of, 45f Growth hormone (GH), 37, 45, 268-269, 283 effect on bone mass, 283 use in JIA, 55 Growth reference charts, 32 female, 34f male, 33f Growth, 32, 268 bones, 268, 279 clinical assessment, 46-52 and development, 31-39 impact of rheumatic disease on, 39-46 infant's length, 32 skeletal growth, 268-269 Gut, 129t manifestation, 129t Gynecomastia, 38

Hair loss, 124, 173 Headaches, 299

in musculoskeletal pain, 222 HEADSS, 75, 315 Health, 352 holistic view, 352 transition, 352-353 Health- and disease-related knowledge, 359 Health care, 371, 380 aim, 384

educational interventions, 371-372 key principles, 4-8 pediatric to adult, 352-357 processes, 384 recent studies, 380-381 settings, 95-96 system of, 383 Health Insurance Portability and

Accountability Act of 1996, 160 Health insurance, 360-361 Health issues, 297, 299, 300-301 asthma, 297, 299 diabetes mellitus, 299 epilepsy, 300 headaches, 299 hypertension, 299 mental health, 302 obesity, 300-301 sexual behavior, 292-295 sexually transmitted diseases, 295-296 substance abuse, 296-297 Health professionals, 66-67, 77, 316, 331-332, 367, 383, 400-409 adherence strategy, 331 communication barriers with young people, 66-67 attitudinal, 67 behavioral, 67 practical, 67 different perspectives, 368-370 factors affecting communication with young people, 67-72 confidentiality, 67-70 environment, 71-72 provider behavior, 70-71 proactive approach, 75 health curricula for, 373 interviewing strategies, 75 lack of training as hindrance services, 370 parental needs, 316

[Health professionals] professionals knowledge, need for improvement, 383-384 responsibilities, 74-75 role in facilitating friendships, 340 training needs, 367-375 trigger questions by, 77-78 views of young people, 400-401 young person's perspective, 415-416 Health status, 291-292 Health-care, 352 different cultures of care, 353-354 pediatric to adult, 352-357 pediatric versus adult, 354 Heel, 260-261

calcaneal apophysitis, 260-261 Height measurement, 47

technique, 47 Height-velocity, calculation, 47 Heliotrope discoloration, eyelids, 121, 121f Henoch-Schonlein purpura (HSP), 117 Herniations, 210, 212

site of, 212 High-quality care, 381 by IOM report, 381 Hip, 252-253 pelvic apophyseal injuries, 253 slipped capital femoral epiphysis, 253, 255 stress fractures, 255-256 Homicide, 304 Honesty, 70

Hormonal regulation, 33

of puberty, 33-38 Hospital settings, 332-334 in-patient settings, 333-334 outpatient settings, 333 HSP. See Henoch-Schonlein purpura Human papillomavirus (HPV), 295 Hydroxychloroquine, 123, 171 for localized scleroderma, 126 for SLE, 172 Hyperextension test, 249f Hypergonadotrophic hypogonadism, 51t Hyperlordosis, 250-252 disc disease, 251-252 SI dysfunction, 252 treatment, 251 Hypermobility, 185 Hyperpigmentation, 124, 129t Hypersensitivity, 186-187

Hypertension, 115, 299 Hypogonadotrophic hypogonadism, 51t Hypopigmentation, 124 Hypothalamic-pituitary-gonadal (HPG), 35

Icing, 239

in knee disorders, 239 Idiopathic inflammatory myositis, 118.

See also Juvenile dermatomyositis (JDM)

Idiopathic juvenile osteoporosis (IJO), 214, 270-271 histonomic studies, 271 pathognomonic feature, 271 symptoms, 271 Idiopathic pain syndromes, 184 Idiopathic scoliosis. See Scoliosis IgA deposition, 117 IgA-dominant immune deposits, 112t IGF-1 activity, 46 Immunosuppressants, 122 first line, 122 for SLE, 172 Immunosuppressive drugs, 113 Impaired future fertility, 173 Improvement knowledge, 384-389, 385 measurement, 385-388 psychology of work and change, 388 system, 384-385 variation, 385-388 Independence, 351 financial implications, 351-352 legalities of adulthood, 351 social security support, 352 Individuals with Disabilities Education Act

(IDEA), 349 Inflammatory bowel disease (IBD), 136 Infliximab, 123, 136 for inflammatory bowel disease, 136 for juvenile dermatomyositis, 123 Inhalants, 297 Injuries, 261 common sports knee injuries, 235, 236t elbow, 262-261 meniscal injuries, 245 pelvic apophyseal injuries, 253 sports shoulder injuries, 258t wrist, 262-263

In-patient settings, 333 Institute for Healthcare Improvement, the, 396

Insulin-like growth factor 1 (IGF-1), 37 International Association for the Study of Pain (IASP), 188 diagnostic criteria for CRPS, 189t International classification of functioning, disability, and health (ICF), 352 International league against rheumatism (ILAR), 149, 153 criteria for enthesitis-related JIA, 153t Internet, 341 Interview strategies, 75 bidirectional approach, 75 unidirectional approach, 75 Intracerebral calcification, 125 Intravenous alendronate, 282 Intravenous pulses, 123 IOM report, 381 Iontophoresis, 245

for patellar tendonitis, 245 IV cyclophosphamide, 173

for SLE, 173 IVIG, 123

JDM. See Juvenile dermatomyositis JIA. See Juvenile idiopathic arthritis Job opportunities, 350-351 Joint contractures, 124 Joints, 129, 154 arthritis, 154

disorders of systemic sclerosis, 129 swelling, 121 Joint pain, 233-248

Jumper's knee. See Patellar tendonitis (PT) Juvenile ankylosing spondylitis. See Enthesitis-related arthritis Juvenile arthritis. See Juvenile idiopathic arthritis

Juvenile chronic arthritis (JCA), 272 Juvenile dermatomyositis (JDM), 118, 120-123 case study, 118 constitutional symptoms, 120 cutaneous abnormalities, 121 Gottron's patches, 121 heliotrope discoloration, eyelids, 121

[Juvenile dermatomyositis (JDM) cutaneous abnormalities]

periungual erythema, 121 disease activity measurement, 122 general symptoms, 120 skin features of, 121 treatment, 122 Juvenile fibromyalgia. See Diffuse idiopathic pain (DIP) Juvenile idiopathic arthritis (JIA), 40-43, 149-163, 215 disease activity, 154

effect on sexual and reproductive health, 160-161

frequency in United Kingdom, 150t growth hormone use in, 55 hospital-based studies, 155t implications for family, 161 long term disability, 158t ocular involvement, 155-156 outcomes, 154-163 patients progress into adulthood, 163 percentage of patients with poor outcomes,

157t prevalence, 149

psychological complications, 158-159 reduced physical ability, 156-157 relationship to adult arthritides, 149-154 enthesitis-related arthritis, 152-153 oligoarticular JIA, 150 psoriatic arthritis, 153-154 rheumatoid factor positive polyarthritis

JIA, 154 systemic onset juvenile idiopathic arthritis, 151-152 and social functioning, 157-158 subtypes, 149-150 surgery for, 155 in women, 160 Juvenile kyphosis, 211-212

Kawasaki disease (KD), 115

symptoms, 115 KD. See Kawasaki disease Knee, 234-241 anterior cruciate ligament, 242 diagram, 234 injury, 234

[Knee injury]

signs of, 234 case study, 237, 240 medial collateral ligament, 242-243 Osgood Schlatter (OS) disease, 240-241 patellofemoral stress syndrome (PFSS), 238-240

Sinding-Larsen-Johansson (SLJ) syndrome, 241

Lachman test, 243f Large vessel vasculitis, 111, 113, 115 clinical presentation, 113 diagnosis, 113 giant cell arteritis, 112 Takayasu's arteritis, 111, 113, 115 Lean body mass, 38

changes during puberty, 38 Leg pain, 198, 256 Leuprolide acetate, 173

for ovarian failure, 173 Ligament, 240-243 anterior cruciate ligament, 242 medial collateral ligament, 243 Limb arthritis, 152 Limited systemic sclerosis, 127 Linear scleroderma, 124, 125f lesions, 125 occurance, 125 symptoms, 124-125 Listening culture, 65-80

creation of, 65-80 Little league elbow. See Medial epicondyle apophysitis Livedo reticularis, 115

Localized idiopathic pain syndrome, 188-189 Localized scleroderma, 124-127 affected areas, 124 ANA in, 126 clinical symptoms, 124 disease course, 126 investigations, 126 management, 126-127 prognosis, 126 systemic therapies, 127 Locked knees, 245 Lordotic mechanical back pain, 210

Low back pain, 225 in disc disease, 251 muscular, 250 in SI dysfunction, 252 in spondylolysis, 248 Low bone mineral density, 267-270 defined, 267

diagnostic methods, 273-279

dual-energy X-ray absorptiometry, 273, 274

quantitative computed tomography, 275-278

quantitative ultrasonography, 276 initial diagnostic work-up for, 277 relevance, 267-268 treatment, 281-283 Low moods, 188

Lumbar disk herniation, 212-213 Lumbosacral strain, 210 Luteinizing hormone (LH), 36-37 high levels, 51t low levels, 51t Lyme disease, 134t Lymphadenopathy, 117, 151

Macrosystem, 384 Macular erythematous, 151 Malaise, 120 in discitis, 217

in juvenile dermatomyositis, 120 Male, 33 facial hair development, 39 growth reference chart, 33 height-velocity chart, 35 onset of puberty, 38

physiological changes during puberty, 38 pubertal development, 39 voice deepening, 39 Malignant tumors, 137, 218-219 musculoskeletal system, 137 spine, 219 Masculinity, 160 Maturation, physical, 33 McConnell taping, 239, 246 Medial collateral ligament (MCL), 242-243

case study, 243 Medial epicondyle apophysitis, 261-262 rehabilitation, 262

Medical disorders. See Health issues Medium vessel vasculitis, 112, 114, 115 incidence, 112t Kawasaki disease, 115 microscopic polyarteritis, 115-116 polyarteritis nodosa, 115 probable causes of, 114t Medroxyprogesterone acetate (MPA), 57 Meniscal injuries, 245 Meniscus, 235, 244-245 Mesosystem, 384 Methotrexate, 44, 109, 122 first-line medication, 122 for juvenile dermatomyositis, 122 Micrognathia, 157

Microscopic polyarteritis (MPA), 115-116 necrotizing crescenteric glomerulonephritis, 115 Microsystem basics, 390-393 Microsystem, 384, 386 Mid-parental height range (MPHR), 32 female child, 32 male child, 32 Mid-transition plan, 321-323 Migratory arthritis, 134t Mobile phones, 340-341 Mood, 331

Morbidity, phychological, 158-160 Morbidity, SLE, 175 bone health, 175 cardiovascular health, 176 mental health, 176

psycheducational functioning, 176-177 Morphea, 124

Mortality, 303. See also Death Motivators, 74

uses of, 74 Motor vehicle accidents (MVAs), 303 MPA. See Microscopic polyarteritis (MPA) MPHR. See Mid-parental height range (MPHR)

Multidisciplinary approach, chronic pain,

199-200 Muscle, 120 wasting, 124 weakness, 120-121 Muscular low back pain, 250-252 Musculoskeletal disequilibrium, 187 Musculoskeletal disorders, 107, 132 in adolescents, 133-135

[Musculoskeletal disorders] epidemiology, 107-108

role in inflammation, 108 infections presenting as, 132 Musculoskeletal pains, 184

diagnostic possibilities for, 195 Musculoskeletal system, 137 benign tumors, 137 malignant tumors, 137-138 Musculoskeletal symptoms, 136 causes of, 136-138

inflammatory bowel disease, 136 systemic disease, 137-137 tumors of the musculoskeletal system, 137-138 Myalgia, 115

for polyarteritis nodosa, 115 Mycophenolate mofetil (MMF), 126, 128, 172t, 173 for localized scleroderma, 126 for SLE, 173 for systemic sclerosis, 128 Mydriatics, 156

Myopathy. See Juvenile dermatomyositis (JDM)

Nail pitting, 153, 215, 224 National arthritis advisory board, 97 National Training Initiative in Adolescent

Health (NTIAH), 373 Necrotising vasculitis, 112t Necrotizing crescenteric glomerulonephritis, 115 Negative communication skills, 314 Nocturnal pain, 219 Nonaccidental injury, 215

as cause of back pain, 214-215 Nonadherence, 21, 87 risk factors, 91-96

condition-related factors, 94 health care provider-related factors, 95-96

patient-related factors, 93-94 socioeconomic factors, 91-92 treatment-related factors, 94-95 prevalence, 87-91 Non-caseating granuloma, 117 Nonpharmacological therapies, 85

Non-pharmacological therapies, adherence to, 89-91 avoidance of risk factors, 90 clinic attendance, 90-91 occupational therapy, 89-90 physical therapy, 89 Nonspecific back pain, 208, 208-209, 225 Non-steroidal anti-inflammatory drugs

(NSAIDs), 88, 239 Normal growth, 31-39 and development, 31-39 puberty, 33-39 stature, 31-33 Nuprin Pain Report, 183

Obesity, 299, 300-301, 369 management, 300 reasons of, 301 Occupational therapy, 89-90 Oedema, 115 in juvenile dermatomyositis, 118 in Kawasaki disease, 115 Oligo-arthritis, 150, 156 outcomes, 156 prevalence, 150 Oligoarticular JIA, 150, 159 Olson's circumplex model, 313-314 One-Stop Career Centers, 350 Onycholysis, 153, 215 Opioids, 225 for low blood pressure, 225 for pain, 199 Oral steroids, 43, 46

impact on growth, 43-44 Oral ulceration, 117

Organizational interventions, 97, 99-100 Osgood Schlatter (OS) disease, 235, 240-241 lateral knee radiograph of, 241f physical examination, 240 treatment, 240-241 Osteoblastoma, 219

Osteochondritis dessicans lesions (OCD), 247-248 tunnel knee radiograph, 247f Osteochondroma, 137, 219 Osteoid osteoma, 137, 219 Osteomyelitis, 132-133, 217-218 causal agents, 133

[Osteomyelitis]

clinical characteristics, 133t Osteoporosis, 154-155, 214, 267, 274 bisphosphonates for, 281 causes of, 214 in children, 274 primary forms, 270-271, 274t idiopathic juvenile osteoporosis (IJO), 270-271 secondary forms, 273, 274t teriparatide for, 283 websites on, 284-285 patients, 284 physicians, 284-285 Osteosarcoma, 137, 219 Outpatient settings, 333 Oxandrolone, 56 for delayed puberty, 57

See also Chronic pain abdomen, 115 areas affected by, 190-192 activity, 190-191 education, 191 family, 191-192 fatigue, 190 future, 192 independence, 191 moods, 191 sleep, 190

social structure, 191 autonomic changes, 188 general features, 186-187 in muscle, 121 musculoskeletal, 184 thermodysregulation during, 187 Pain education, 197-199 Pain intensity measurement, 196 Pain perception, 22, 196 in adolescents, 22 factors, 22 Pain spider, 196, 196f Pain-associated disability, 186, 190f Pamidronate, 136

PAN. See Polyarteritis nodosa (PAN) Parental needs, 316 assessment, 316

Parental supervision, 99 Parenting, 311-324 Parents, 312, 340 concurrent visits, 319-320 mid-transition plan, 321-323 role during development, 312 role in self-advocacy skills training, 320 signposting resources for, 320 tips for, 318t web-based resources for, 324 Parry-Romberg syndrome, 125-126 Pars interarticularis, 210-211, 250f Patellar dislocation, 236t, 246 case study, 246 mechanism of injury, 236t treatment, 246 Patellar instability, 238f apprehension test for, 238f Patellar tendon strap, 241, 245 Patellar tendonitis (PT), 236t, 245 case study, 245 treatment, 245 Patellofemoral stress syndrome (PFSS), 235t, 238-240 management, 239 physical examination, 238 Path to Health Care Excellence Toolkit:

Quality by Design, A, 393 Pathogenesis, 184

chronic pain, 184-186 PDSA model, 394 Pediatrics, 276 clinical problems with bone mass measurement, 276-278

Peer, 338 counselors, 339 mediators, 338-339 mentors, 338 Peer groups, 99

Peer support, 110t, 330, 332-334, 336 benefits, 342

hospital settings, 331-334 in-patient settings, 333-334 outpatient settings, 333 modern technologies and, 340-341 mobile phones, 340-341 internet, 341 potential of clinic waiting areas in, 334f summer camps, 334

trigger questions to determine levels of, 342t

Peer support schemes, 338-339 anti-bullying policies, 339 peer counselors, 339 peer mediators, 338 peer mentors, 338 student councils, 338 Pelvic apophyseal injuries, 253, 254t case study, 253 Penicillin prophylaxis, 116 Periodic fever syndromes, 138 Castleman's disease, 139 familial Mediterranean fever, 138-139 Periorbital edema, 120 Periungual erythema, 121 PFSS. See Patellofemoral stress syndrome Pharmacological therapies, 88

adherence to, 88 Phenytoin, 127

for scleroderma, 127 Physical activity, 270, 281, 301-302 Physical disability, 162 Physical maturation, 33

role of pubertal process, 33 Physical therapy, 89 Piaget's model of cognitive stages, 14 Plan-Do-Study-Act (PDSA) cycle, 389 Planning, importance, 320 Plaques, 124 Plasma exchange, 123 Plastic surgery, 127 Polyarteritis nodosa (PAN), 115 symptoms, 115 treatment, 115 Polyarthritis, 150-151 Polycystic ovary syndrome, 53t Polymorphous exanthema, 115 Polymyositis, 118 Polypharmacy, 95 Poor adherence, 86-95, 100 potential risk factors, 92t Positive communication skills, 314 Postinfectious myositis, 135t Post-secondary education, 349-351 Prader orchidometer, 43f Prednisolone, 46, 55 Prednisone, 172 doses in, 172 for SLE, 172 Pregnancy in adolescence, 294-295 factors contributing to, 294

[Pregnancy in adolescence] in various counties, 294 Premature atherosclerosis, 176 Premature ovarian failure, 173 Professional knowledge, 383-384 Progressive systemic sclerosis. See Systemic sclerosis

Prosthetic joint replacement, 155 Protein intake, 280-281

bone health promotion, 280-281 Proteolysis, 46

Provider behavior, 70-71, 368.

See also Health professionals Pseudoporphyria, 94 Psoralen, 127 Psoriasis, 153-154 Psoriatic arthritis, 153-154, 215 dactylitis, 153 psoriasis, 153 Psychosocial functioning, 22 impact of illness on, 22-24 and rheumatic diseases, 22 Psychosocial issues, 75, 334 in individualized transition plans, 75-76

Psychosocial support, 97, 99 and adherence, 99 interventions to increase, 99 Pubertal delay, 49 assessment, 49

trigger questions, 49 differential diagnosis, 51-52 symptoms and sign, 49-50 Pubertal development, 40 average age of, 40t in females, 39f in males, 39f

Prader orchidometer for, 43f Pubertal onset, 37 Puberty, 32-50, 269 changing percentiles, 32 delayed, 49-50

effect on bone mass, 269-270 hormonal regulation, 33-38 influencing factor of, 37, 49 onset of, 38-39

physical changes during, 38-39 Pustulosis, 132, 136 Pyomyositis, 135t causal agents, 135t

Quality adolescent healthcare provision, 71 Quality health care, 70

key attributes, 70 Quality improvement, 381-390 aims, 382 defined, 381

improvement knowledge, 384-389 professional knowledge, 383-384 requirements, 381-390 Quantitative computed tomography (QCT), 275-276

Quantitative ultrasonography (QUS), 276 advantages, 276

macular erythematous, 151 Raynaud's phenomenon, 124 Reactive arthritis, 133t causal agents, 133t clinical characteristics, 133t Red eye, 155

Rehabilitation, chronic pain, 199-200 chronic pain, 199-200 medical therapies, 199 multidisciplinary approach, 199-200 medial epicondyle apophysis, 262 PFSS, 239 Reproductive health, 160 Residential camps, 334-335

Birmingham, U.K. model, 335 Residential trips, 337t Resilience, 24-26 categories, 25 defined, 24 key elements, 25 community level, 25 dispositional attributes of child, 25 family level, 25 researches on, 24-25 Respect, significance of, 77 Respiratory tract, 116 lesions, 116 use of septrin, 117 Rhabdomyosarcoma, 138 Rheumatic disease, 19, 40, 107, 271, 318, 349 in absence of steroids, 43-44 and adolescence, 19-24 diversity, 19-21

[Rheumatic disease and adolescence]

spectrum, 19-21 developmental influences on perception, 21-24

adolescent pain perception, 22 nonadherence, 21 effect on bone density, 271-273 effect on growth and development, 39-46 growth failure, 40 growth failure, 44 impact on development, 22-24 issues in, 109-110

mechanisms of growth failure in, 45 mid transition plan for parents, 321 by oral steroids, 43 post-secondary education, 349-351 in prepubertal young people, 54 psychosocial impact, 22-24 pubertal delay, 40 in prepubertal young people, 54 treatment, 318t tips for dealing with parents, 318t Rheumatoid arthritis (RA), 154 Rheumatoid factor negative polyarthritis

JIA, 150-151 Rheumatoid factor positive polyarthritis

JIA, 154 Rheumatoid nodules, 154 Rheumatology, 2 epidemiology, 2-3 key players 6-7 Rheumatology clinic settings, 317 strategies for working with parents, 317-320 clinic visits, 319

communication strategies, 317-318 environmental aspects, 317 importance of planning, 320 Rheumatology microsystem, 393-396 assessment, 393-394 diagnosis, 395 follow through, 396 treatment with, 393-395 Rheumatology service delivery, 73 Ring injuries, 213 Risk taking behavior, 21 Rituximab, 123, 172, 173 Rocky Mountain spotted fever, 114t Roth-Isigkeit study, 189

Royal College of Pediatrics and Child Health, 372

Sacroiliac (SI) joint, 252 Saddle-nose deformities, 116 Sarcoid, 117 clinical symptoms, 117 steroid treatment, 117 Scarring, 127, 171 Scheuermann's disease, 211-212 School absence, 74, 89, 359 School absenteeism, 86 Schools, 335-340, 349 activity clubs, 338 anti-bullying policy, 339 graduation from, 349 peer support schemes, 338-339 role of other school personnel, 339 role of teachers, 336-338 School-to-Work Opportunities Act of 1994, 350 Scleroderma en coup de saber, 124 Scleroderma, 123, 124 in childhood, 123-124 Raynaud's phenomenon, 124 Scoliosis, 213 Second line agents, 136 Secondary amenorrhea, 53 Secondary sexual characteristics, 38 five-stage pubertal progression, 38 Secondary vasculitis, 114t causes of, 114t Self-determination, 347-349 through childhood and adolescence, 347-348

Self-efficacy, 20, 24, 93, 98, 160 increment, 98-99 low sense, 20 Self-management, 3, 6, 98 Self-regulatory theory, 93 Septic arthritis, 133t Serial monogamy, 293 Sever's disease, 260-261 Sex steroids, 56

short courses, 56 Sexual behavior, 109, 292-295 adolescent pregnancy, 293-295 issues, 109t

[Sexual behavior issues]

possible solutions, 109t statistics, 292-293 Sexually transmitted diseases, 295-296 associated factors in, 296 causal agents, 295 Shared leadership model, 323t Shock absorbers. See Meniscus Short stature, 40, 44, 48-49 causes of, 40 clinical examples, 57-59 differential diagnosis, 48 management, 52, 54-56 treatment, 54 Shoulder, 256-259 multidirectional instability of the shoulder causing impingement, 257, 259 pain in, 256

sports shoulder injuries, 258t SI dysfunction, 252

case study, 252 Sicca syndrome, 155 Sinding-Larsen-Johansson (SLJ)

syndrome, 242 Single photon emission computed tomography (SPECT), 248 Skeletal growth, 268-269 Skills training, 68, 79-80, 358-359 Skin, 124 dysplasia, 126 erythema, 124

manifestations in systemic sclerosis, 129 SLE. See Systemic lupus erythematosus Sleep disorders, 189-190 Slipped capital femoral epiphysis (SCFE),

253, 255, 256f Slowed growth, 174-175 Small vessel vasculitis, 112, 117 causes of, 114t

Henoch-Schonlein purpura (HSP), 117 incidence of, 112 Smoking, 171, 226 risks in SLE, 171 Social security support, 352 Socioeconomic risk factors, 91-92 Special health care needs (SHCN), 345

critical junctures for young people with, 345 Spiking fever, 151 Spinal cord anomalies, 214

Spine pain, 223, 251 Splinting, 89 Spondolisthesis, 249 Spondyloarthropathy, 152 Spondylolisthesis, 210-211 Spondylolysis, 210-211, 248-250 case study, 250 treatment, 249 Sports, 211, 248 and back pain, 211, 248-250 in relation to joint pain, 233-248 Sports injury, 246 Sports shoulder injuries, 258t Sprains, 210 Stadiometer, 47

Staphylococcus aureus, 135t, 217 Stature, 31-33, 46 assessment, 46-49

height velocity calculation, 47, 49 measuring technique, 47 Status inequality, 77

lessening of, 77 Steroids, 43-44, 56, 171 for sarcoid, 117 for scleroderma, 126 for SLE, 171-173 Stiffness, 121, 218 in discitis, 217 in JIA, 215 Still's disease. See Systemic onset juvenile idiopathic arthritis Stork test, 248 Strain, defined, 314 Stress fractures, 255

case study, 255 Stressor, defined, 314 Student councils, 338 Subglottic stenosis, 116 Subluxations, 246 Substance abuse, 296-297, 298t epidemiology in Europe, 298t Successful transition planning, 346 Suicide deaths, 303-304

in various countries (1991 to 1993), 304t Sulphasalazine, 59, 127 for systemic onset juvenile idiopathic arthritis, 152 for systemic therapies, 127 Summer camps, 334-335 Supplemental Security Income (SSI), 352

Support groups, 324, 341 Swedish Rheumatology Registry, The, 387t Sweet Talk project, 340 Swelling, 120 face, 120-121 joints, 121 Symmetrical polyarthritis, 134t Synovitis, 124

in familial Mediterranean fever, 138 Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome, 136 Syphilis, 114t

Systemic connective tissue diseases, 118-123 case study, 118, 120 juvenile dermatomyositis, 118, 120-123 systemic lupus erythematosus, 118, 169-178 Systemic lupus erythematosus (SLE), 169-178 average age at diagnosis, 170 bone health, 175 cardiovascular health, 175 CNS involvement, 176-177 difficulty in following treatment program, 170 epidemiology, 169-170 general concepts, 170 health issues, 171

immunosuppressant treatment, 173 long-term outcomes, 177-178 management, 170-175 medication, 172-174 normal teen lifestyle, 174-175 medications used in the management, 172 mental health, 175

modifiers for improved outcomes, 177 optimal care, 170 psycheducational functioning, 175 pubertal, 174

risk factors for accelerated atherosclerosis, 176 Systemic Lupus International Collaborative

Clinics, 178 Systemic onset juvenile idiopathic arthritis, 151-152 active disease duration, 151 differential diagnosis, 151 Systemic sclerosis, 127-132 clinical manifestations, 129t-131t investigations, 128 overlap syndromes, 132 prognosis, 128

[Systemic sclerosis]

treatment, 128 Systemic vasculitis, 110-118 Behcet's disease, 117-118 classification, 111 defined, 111

granulomatous, 116-117 large vessel vasculitis, 111, 113-115 medium vessel vasculitis, 115-116 nomenclature, 112t sarcoid, 117

small vessel vasculitis, 117 Systems of health care, 385f

Tachycardia, 187

Takayasu's arteritis, 111-112, 115

incidence, 112 Tanner stages, 41f Teachers, 336-338, 372-374 as role models, 336 role in friendship, 336-338 Teenage brain, 13-26 developmental issues, 14-19 resilience, 24-25 and rheumatic diseases, 19-24 Teeth, 125f stunned growth, 125f Tendonitis, 245 Teriparatide, 283 Testosterone, 37 Testosterone enanthate, 56, 57

doses, 56 Therapy, 89 occupational, 89 physical, 89 Therapy-related questions, 78t Thermodysregulation, perceived, 187 Tibial tuberosity, 240-241 Tigger questions, 77-79 about general health, 78t disease-related, 78t therapy-related, 78t To Err Is Human: Building a Safer Health System, reports, 380 current situation, 380-381 Topical corticosteroids, 156 Trabecular bone density, 269 Training programs, 372-374

Transition, 345, 355-356 checklist, 355t defined, 346 general principles, 346 goals, 345 key elements, 347 models, 357 planning, 358

professional training for, 354

role of vocational rehabilitation agencies,

350-351 web-based resources, 348 Transition models, 357-361 Transitional care programs, 357

key components, 357-358 Transitional care, 66, 317, 353, 357 best practice in, 66 in practical terms, 75 Transitional vertebrae, 214 Treatment-related risk factors, 95 Triadic consultation, 76 Tricyclic antidepressants, 199, 225

for low back pain, 225 Tumor necrosis factor receptor associated periodic syndrome (TRAPS), 138 Tumors, 218-219 of bones, 219 spinal tumors, 218-219 musculoskeletal system, 137-138 Turn-taking, 76, 317-318 Type II pauciarticular arthritis. See Enthesitis-related arthritis

Unidirectional interview strategy, 75 Uveitis, 136, 152, 155-156 outcomes, 156

and visual impairment, 155-156

Valgus stress, knee, 242, 245 Vascular activation, 123

parameters, 123 Vascular imaging, 113 Vasculitides. See Systemic vasculitis Vasodilators, 130t Velocity chart, 35f-36f female height, 36f male height, 35f

Verbal plan, consultation, 76 Vertebral osteomyelitis, 217 Violence, 302-303

and mortality, 303 Viral arthritis, 134t

Visual Analogue Scale (VAS), 122, 196 Visual impairment, 155-156 Vitamin D, 280

Vocational rehabilitation agencies, 350-351 Voice deepening, 39

Weakness, 120

muscle, 120-121, 123 Web resources, 226-227, 284-285 back pain, 226-227 osteoporosis, 284-285 transtition, 348t for parents, 324 Wegener's granulomatosis (WG), 116

symptoms, 116 Weight loss, 117 in inflammatory bowel disease, 136 in sarcoid, 117 in tumors, 218 Well-being questions, 78t Workforce Improvement Act of 1998, 350 Wrist splints, 89 Wrist, 263-264 chronic Salter Harris I fractures of distal radius, 263-264

Xerostomia, 129t

Young people, 80, 400 expectations with health professionals, 400-401

views for health professionals, 400-401,

410-411 wish from professionals, 80 Youth risk behavior survey (YRBS), 292

in 2005, 301 Youth violence, 302-304

Z-score, 276

Rheumatology about the book...

Adolescent Rheumatology is the first single-source text that focuses on how adolescent-specific aspects impact on rheumatic conditions, and cross references disease-specific information from general rheumatology textbooks. Using a generic, developmental approach to make this book unique, the evidence base is referenced with a clinical and practical approach that is adopted to each topic.

Written by a list of international experts from a range of disciplines, chapter topics include:

• differences in presentation, diagnosis and management between pediatric, adolescent and adult rheumatology care

• adolescent health training issues

• quality of care in adolescent rheumatology

• communication with young people

• a full chapter written by young people attending adolescent rheumatology clinics

This guide also covers core adolescent health topics and how these factors are impacted by rheumatic disease, which includes:

• chronic idiopathic pain

• cognitive development

• communication about the editors...

generic health issues growth and puberty juvenile idiopathic arthritis low bone density peer support

1 parenting of adolescents > SLE

sports injuries transitioning to adult health care

JANET E. MCDONAGH is Clinical Senior Lecturer in Pediatric Rheumatology, Division of Reproductive and Child Health, University of Birmingham and Birmingham Children's Hospital, UK. She received her medical training from the University of Newcastle, Tyne Medical School, UK. Dr. McDonagh's current research is focused in transitional care for young people with chronic rheumatic diseases, the long-term outcome of rheumatic diseases developing with onset in childhood, and development of adolescent health training for pediatric and adult providers. She has also written over 60 peer-reviewed articles and 9 book chapters relating to the subject of rheumatology and/or adolescent health.

PATIENCE H. WHITE is Professor of Medicine and Pediatrics, George Washington University School of Medicine and Health Sciences Washington, DC, and Chief Public Health Officer, Arthritis Foundation, Washington, DC. She received her M.D. from Harvard School of Medicine, Cambridge, Massachusetts, and a M.Ed. from George Washington University School of Education in Washington, DC. Some of her current research involves improving the health of people with arthritis through education, facilitating health system change for quality care for people with arthritis, and improving the long-term outcomes for youth with chronic illnesses and disabilities. She has been a consultant to the youth subcommittee of the US President's Task Force for Employment of Adults with Disabilities. She created and served for 15 years as the executive director of a transition to independence program for youth with chronic illnesses and disabilities, the Adolescent Employment Readiness Center at Children's National Medical Center in Washington, DC. She has published over 49 peer-reviewed articles and 35 books and chapters in the fields of rheumatology and medical education.

Diet Tweak System

Diet Tweak System

Trying To Lose Weight Can Be Tough. But... Not Losing Weight and Gaining What You Lost Back, Sucks. If you've ever felt that no matter what you do to lose weight nothing seems to work. If you've ever felt that there has got to be some kind of a system or way to lose weight...but just have not found it yet.

Get My Free Ebook


Post a comment